Introduction The role of drugs in the occurrence of multiple sclerosis (MS) is perceived to be insufficiently investigated. Objective The aim of this study was to map and assess the evidence on MS occurrence after drug exposure, in order to identify possible signals of causal association. Methods A search strategy was performed in MEDLINE and Embase as of July 2016; references consistent with the aim of the study were analysed to extract relevant measures of causal association between drugs and MS. The Newcastle-Ottawa Scale and appropriate guidelines from the International Society for Pharmacoepidemiology (ISPE) and the International Society of Pharmacovigilance (ISoP) were used to assess the quality of included studies. Results After screening 832 articles, 58 were selected (of which 14 were found by checking the reference lists of reviews): 30 case reports and case series, 24 longitudinal studies and four randomized controlled trials. Seven longitudinal studies had good (at least 7 out of 9) quality scores, whereas case reports/case series presented several limitations. Half of included articles focused on immunomodulatory drugs (etanercept, infliximab and adalimumab), especially in case reports/series, suggesting an association with MS occurrence. Contraceptives and antibacterials were investigated in some population-based studies, without definite results. Conclusion A heterogeneous pharmacological profile of identified classes emerged. Low strength of evidence and conflicting results highlighted the difficulties in addressing the possible contribution of drugs in MS occurrence. Methodological advances are needed, especially to control the confounding role of underlying disease for specific drug classes.
Introduction
Multiple sclerosis (MS) is a neurodegenerative disease especially affecting young women (aged 20-40 years). Patients with MS can suffer physical and mental disability in both early and late stages of the disease.
Prevalence of MS increases progressively with geographical latitude: from \5/100,000 inhabitants in Southeastern Asia, Equatorial Africa and Central America, to [100/100,000 in Northern America and Northern Europe. Exceptions are represented by Sardinia with high frequency of disease, and Inuit people in Canada with low frequency [1, 2] .
Different risk factors have been associated with the disease: low blood vitamin D level [3] , smoking [4, 5] , viral infection [6] , place of birth [7] and genetic factors [8] .
While a large body of evidence exists on the role of environmental and genetic risk factors in MS pathogenesis [9] , the possible contribution of drugs to MS onset or worsening is uncertain and perceived to be insufficiently investigated in the literature. The hypothesis that some drugs could trigger demyelinating disorders was suggested by Deepak and colleagues, who found an association between tumour necrosis factor inhibitors (TNFi) and demyelinating disorders (Guillain-Barré syndromes, optic neuritis and demyelinating polyneuropathy) [10] in the FDA's Adverse Event Reporting System (FAERS). The complexity of MS in terms of pathogenesis and course of the disease makes the role of drug exposure in MS occurrence particularly challenging to identify.
The aim of this study was to map and assess currently available clinical evidence on the possible role of drug exposure in the onset or worsening of MS, through a systematic search of the literature, focusing on both strength and quality of evidence and addressing unsettled methodological issues. Identification of preliminary signals of risk for specific drug classes could direct future research in this uncertain field.
Methods

Literature Selection
The systematic search of the literature was performed by adapting the methodology reported by the Global Evidence Mapping Initiative [11] . In this study, the descriptive map of available research evidence (i.e. evidence mapping) involved detailed coding of included studies and a series of in-depth syntheses, which assessed available research in terms of study design, number of included patients, specific outcome (i.e. onset or worsening of MS) and relevant measure of risk, as well as level of evidence.
The following search strategy was used both in MED-LINE and Embase databases on July 1, 2016: 'multiple sclerosis/epidemiology' [MAJR] AND (drug* or medication* or medicine*) OR 'multiple sclerosis/chemically induced'. Activated filters were 'English language' and 'human species'.
Duplicates were removed and articles were screened by reading the abstract; the full text was considered when the abstract did not provide clear information about drug/ disease or when it was not available. In order to identify possible additional articles, snowballing was performed on reviews (i.e. reference lists were checked). Snowballing enabled the inclusion of articles previously excluded due to the absence of specific keywords in both MEDLINE and Embase databases. Studies lacking information on drug exposure or on MS onset/worsening were excluded, as well as molecular, animal, prevalence and/or incidence studies. Articles dealing with therapies used in patients with MS and vaccines were also excluded. In order to fully cover the spectrum of the evidence and avoid selective reporting, our review included articles with positive (i.e. increased MS onset/worsening), inverse (i.e., protective effect on MS occurrence) and no association between drug exposure and MS. The website ClinicalTrials.gov was also explored in order to collect potential additional records, using 'multiple sclerosis' as the search term in the outcome field.
The included articles were classified into the following categories: randomized controlled trial (RCT), cohort study or case-control study and case report/case series. Then, each article was assigned to the 'MS onset' and/or the 'MS worsening' group.
Analysis of Causality
Appropriate indicators were identified in each type of study to assess causality: incidence rate for RCTs; odds ratio (OR), relative risk (RR) and other relevant indicators for cohort and case-control studies; Naranjo score for case reports and case series. The Naranjo algorithm is a recognized method for estimating the association between an observed adverse event and the suspected drug, through 10 questions, with weighted answers. The score is classified as follows: B0 doubtful, 1-4 possible, 5-8 probable, C9 definite [12] .
Studies were also classified according to the direction of the association: : for positive association (increased risk of disease or worsening progression), ; for inverse association (reduced risk of disease or delay in disease progression) and $ for no association.
Quality Assessment
Individual quality of included studies was assessed according to the type of evidence and performed in blind by five authors. Disagreements were resolved through discussion. The Newcastle-Ottawa Scale (NOS) for cohort and case-control designs was applied [13] ; for case reports/case series, the guideline endorsed by the International Society for Pharmacoepidemiology (ISPE) and International Society of Pharmacovigilance (ISoP) [14] was used to evaluate the completeness of information. Four key items were considered (title, patient and drug information, adverse event and discussion) and scored based on presence (Y), partial presence (P) or absence (N) of specific information. As regards RCTs, quality assessment was not performed, considering that the rarity of MS and the long latency of the disease do not allow these events to be easily studied within the relatively limited follow-up of a clinical trial, unless it occurs unexpectedly. Therefore, accuracy in detecting MS cases as adverse events in a clinical trial cannot be strictly correlated to its quality.
Results
The search strategy identified 713 records in MEDLINE and 128 in Embase, with nine duplicates. The 832 potential articles were screened and 44 of them were included in our analysis. Fourteen additional articles were identified through snowballing of five appropriate reviews (Fig. 1) . From the 58 included articles, 80 different drug-event pairs were identified: 66 of them focused on the onset of MS, mostly case reports (24) and case control studies (25) . Fourteen records focused on MS worsening, mostly cohort studies (6) and randomized controlled trials (4; Tables 1,   2 ). No additional records were retrieved from ClinicalTrials.gov.
Immunomodulating drugs were the most frequently reported (31 articles): 23 were case reports/case series, all concerning adalimumab [15] [16] [17] [18] [19] [20] [21] [22] , etanercept [15, [22] [23] [24] [25] [26] [27] [28] [29] , infliximab [15, 22, [30] [31] [32] [33] [34] and interferon alfa [35, 36] . The Drugs acting on immunity system (24) Adalimumab :
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A single article may count as many fold as the number of drug-event pairs investigated. A single article may be cited in both Tables 1 and 2 : increased risk, ; decreased risk, $ no association, DMARDs disease-modifying antirheumatic drugs, RCT randomized controlled trials, TNF tumour necrosis factor association was defined as 'possible' or 'probable' according to the Naranjo score, (see electronic supplementary material, Appendix A, Table 1 ). Analytical studies provided conflicting results: the cohort studies did not find any association between exposure to either TNFi or infliximab and MS onset [37] ; the nested case-control studies showed an increase of MS onset with anakinra (RR 2.23; 95% Cl 1.42-3.49) whereas TNFi showed an apparent protective effect (RR 0.56; 95% Cl 0.34-0.90) [38] . Moreover, four clinical trials found worsening of disease in patients treated with interferon-c [39] , atecicept [40] , TNFi [41] and lenercept [42] . Sixteen studies focused on hormonal therapies. Oral contraceptives were the most investigated class, with conflicting results: a possible relationship between the use of an oral contraceptive and MS onset was found in one casecontrol study [43] , whereas a protective effect on onset/worsening was shown in three other cohort studies [44] [45] [46] and a second case-control study [47] ; three additional cohort studies did not find any associations between use of oral contraceptives and onset of disease [48] [49] [50] . Concerning other hormonal therapies, assisted reproduction treatment (ART) showed an increase of MS relapses in three articles: two cohort studies [51, 52] and one case series [53] .
Some evidence was published on drugs active on the central nervous system. A possible association between exposure to anaesthetics and increased MS risk was investigated in four population-based studies: two cohort studies showed an increased risk to develop MS after anaesthesia [54, 55] , whereas one case-control study found no association [56] ; an additional cohort study did not find any association with MS worsening [57] . Case reports (4) and case series (5) suggested the presence of an association between fluoxetine [58] and carbamazepine [59] and an increased risk of MS worsening. A cohort study suggested a possible causal relationship between exposure to valproic acid and onset of disease (hazard ratio 2.41; 95% CI 1.32-4.43) [60] .
Two population-based case-control studies explored a possible correlation between antibacterial exposure and MS onset, with discordant results: Alonso and colleagues [61] suggested a protective role of penicillin (OR 0.5; 95% CI 0.3-0.9), but no relevant effects of other antibacterials (OR 1.3; 95% CI 0.5-3.2), whereas Norgaard et al. [62] found an increased risk of MS onset for both penicillin (OR 1.21; 95% CI 1.10-1.27) and other antibacterials (OR 1.41; 95% CI 1.29-1.53). Moreover, one case series reported a possible association between ethambutol and MS onset risk [63] . HIV treatment showed a reduction of MS incidence in one cohort study (RR 0.38; 95% CI 0.15-0.79) [64] .
MS onset was also reported to be associated with sulfasalazine (one case report) [65] , rimonabant (one case report) [66] , and drug abuse (one case-control study) [67] , while one cohort study did not find a statistically significant association between amiloride exposure and MS onset/worsening risk [68] . Finally, in a nested case-control study, histamine 1 (H 1 ) receptor blockers showed a seemingly protective effect on MS onset (OR 0.2; 95% CI 0.1-0.9) [69] .
Only a minority of longitudinal studies received a highquality score (i.e. at least 7 out of 9) after NOS application: four case-control (out of 8) and three cohort studies (out of 
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A single article may count as many fold as the number of drug-event pairs investigated. A single article may be cited in both Tables 1 and 2 : increased risk, ; decreased risk, $ no association, RCT randomized controlled trials, TNF tumour necrosis factor 16). As regards case-control studies, low-quality exposure ascertainment (either non-blinded interview or written selfreport/medical records) and lack of data on non-response rate were the most frequent limitations, whereas comparability between cases and controls and adequacy of case definition were appropriately addressed in all studies (Fig. 2) . The four high-quality case-control studies investigated contraceptives [43, 47] , antibacterials [61] and H 1 receptor blockers [69] (see electronic supplementary material, Appendix A, Table 2 ). Cohort studies were less homogeneous from a methodological point of view and the main limitations were represented by the following items: duration of follow-up was inadequate to observe possible MS occurrence, comparability of the cohorts was not guaranteed by study design and absence of MS before exposure was not appropriately verified (Fig. 3) . The three good quality cohort studies concerned contraceptive [45] , valproic acid [60] and amiloride use [68] (see electronic supplementary material, Appendix A, Table 3 ). Figure 4 shows the case report/case series quality assessment. A good completeness of information was reported for demographic and clinical description of cases, identification of suspected drugs (generally mentioned in the title) and discussion of previous reports, as well as the possible mechanism involved in the observed adverse reaction. Missing or incomplete information was found for medical status, physical examination, dosage and administration of suspected drug, concomitant therapies and adverse event assessment (detailed information in electronic material, Appendix A, Table 4 ).
Discussion
Evidence mapping on the possible association between drug exposure and MS occurrence identified immunomodulating agents, antibacterials and sex hormones as the drug classes more frequently investigated for this risk. Available information derived mostly from case reports followed by observational analytical studies, whereas RCTs were only rarely a useful source of data on this topic (especially because of rarity and latency of MS occurrence throughout the planned follow-up).
From a methodological point of view, we are aware that the main pathophysiological mechanisms of MS, a multifactorial disease with a long period of latency between biological trigger and clinical manifestation, make the evaluation of a causal role of drugs very difficult. Moreover, we cannot exclude the existence of any publication bias (e.g. unpublished RCTs reporting potential increased risk, missing specific reporting of MS occurrence in published literature), although our search of the ClinicalTrials.gov website did not yield results. This finding also confirms that the clinical trial is not the current ideal design to assess the association between drug exposure and MS.
In this context, case reports and case series remain the most exploitable sources of evidence to raise hypotheses of this possible drug-event relationship. Therefore, the quality of case reports represents a key methodological aspect requiring standardization. In particular, data on medical history and physical examination, together with dose and route of administration of the suspected drug, concomitant Box 1 Room for improvements in study protocols therapies and a detailed description of the adverse event are needed to fully analyse the link between MS and suspected drugs. We encourage clinicians and researchers to provide all clinical elements in future case reports; this will allow proper causality assessment, which will also be of great value for a meta-analytical approach (see also Box 1). Secondary analyses will help to identify any comorbidities possibly triggering MS symptoms as well as concomitant drugs that may increase the likelihood of MS onset by suspected drug (negative synergic effect).
As for observational studies, the paucity and the low quality of data call for future properly designed investigations. In fact, population-based studies are undoubtedly a useful source to test the contribution of drug exposure on MS disease on a large scale; however, no clear study design, lack of specific drug information (doses, exposure frequency and concomitant therapies) and differences in follow-up period make comparison and generalization of results complicated. MS is a multifactorial disease with a long latency, therefore focus on drug exposure without any information on other risk factors, previous/concomitant disease or treatments could represent a bias in this field. In this scenario, collection of details on socio-demographic characteristics, all drug therapies and, when feasible, genetic laboratory data can improve identification of the actual role of drugs as an additional cause of MS disease, inferring a possible pathophysiological mechanism involved in the observed event as well.
As regards the search strategy, it should be recognized that MS cannot be considered a well known adverse event, thus making the use of standard keywords and MeSH terms (e.g. 'chemically induced MS') not sensitive enough to capture pertinent articles. This is the reason why a snowballing procedure was undertaken on initial references and several articles were additionally identified. Recognizing MS as a possible adverse event with a set of specific keywords and MeSH terminologies might contribute to a better classification of publications with a consequent increase in available evidence. If future articles are properly indexed, the gathered evidence can direct animal and molecular studies in order to find a biological plausibility for the epidemiological evidence.
Antibodies against TNFi, especially those used for Crohn's disease, psoriasis and rheumatoid arthritis, were investigated in half of the articles. Almost all these records are represented by case reports, in which the timeline of events followed the same framework: autoimmune disease diagnosis, treatment with immunomodulating therapy, onset of MS, withdrawal of treatment and rapid recovery from MS symptoms after intravenous glucocorticoid administration. However, the time lag between exposure and outcome was largely variable. A specific case was represented by atacicept, which was investigated in parallel by ATON (ATacicept in Optic Neuritis) [40] and ATAMS (ATAcicept in MS) [70] clinical studies for its possible beneficial role in MS disease. ATAM was prematurely interrupted due to an apparent paradox of increased frequency of relapse observed in MS patients; subsequently ATOM was discontinued as well. As regards possible biological plausibility, TNFi could trigger the demyelination process or unmask subclinical MS disease in patients predisposed for autoimmune diseases [71] [72] [73] [74] . Additionally, a pharmacovigilance study by Deepak et al. [10] found increased reporting of neurological events (optic neuritis, transverse myelitis and MS) in TNFi users; this type of study does not allow researchers to strictly assess the drug-event relationship, but it may strengthen the evidence on this specific clinical sequence.
A causal relationship between exposure to sex hormone analogues and MS risk appears controversial, especially in the light of the low quality of studies: only three out of eight studies were of high quality (NOS score of at least 7) [43, 45, 47] . Some studies included in our mapping documented a decrease of MS progression in contraceptive users; on the other hand, ART (i.e. high doses of estroprogestinic agonists) showed a positive association with increase in MS activity, especially in the period where pills were withdrawn between cycles [75] . As suggested by Alonso and Clark [76] and Hawkes [77] , heterogeneity in contraceptive exposure (specifically agents and dose) and in study design prevented an appropriate meta-analysis of available data from being performed; moreover, differences in social variables between exposed patients and controls may represent an additional unmeasurable confounding factor. Apart from drug exposure, significant remission of MS in the third trimester of pregnancy and increase in relapses after delivery have been documented by numerous studies (e.g., the PRIMS [PRegnancy In Multiple Sclerosis] study [57] ). Fluctuation in hormonal levels observed during pregnancy, ART and contraception could be crucial to understanding the relationship between sex hormones and MS. The immunomodulating power of estrogens and their potential anti-inflammatory and neuroprotective effects, on both T helper and B cells, have been demonstrated by human and animal studies, and could explain why during both pregnancy and hormonal therapy women do not experience relapses [75, [78] [79] [80] [81] .
The literature on antibacterials also showed conflicting results. Norgaard et al. [62] found increased risk for developing MS in patients receiving antibacterials, in particular after at least 5 years from the last exposure and in subjects with a C. pneumonia infection. On the contrary, the study by Alonso et al. [61] , ranked as good quality, did not find any association between antibacterial exposure and MS, when considering a 3-year observational period. The debate on this topic includes the possible role of bacterial infections on MS development, as previously shown for viral infection [77] . Antibacterials, indeed, could represent a proxy of actual causal exposure (infection) instead of a direct risk factor. In this context, recent studies showed a possible influence of the gut microbiota in MS onset or worsening: alteration of gut microbiota (due to antibacterial exposure or environmental factors) was found in patients affected by MS or another autoimmune system disease [82] . In the light of the current debate, future studies on antibacterial exposure and MS risk should consider longer follow-up periods, cumulative doses, age at exposure and pathogen characteristics to better define the role of antibacterials and infections in MS pathogenesis.
As for anaesthetics, they are largely used in general and/ or local surgery, also in patients with MS, although possible association between exposure to these agents and onset/worsening of MS is debated [83] . Considering the absence of specific guidelines for anaesthetic use in MS patients, further analytical studies focused on general/locally used anaesthetic could clarify the relationship with the disease.
In a case report, rimonabant, a cannabinoid receptor antagonist used in obesity treatment and already withdrawn in many countries, was suggested as possibly responsible for MS occurrence. Moreover, oro-mucosal preparations of cannabinoid analogues are now available for spasm control in MS patients and a multicenter population-based study suggested an acceptable risk-benefit profile [84] . These data stimulate translational research to clarify the possible influence of the endocannabinoid system on neurodegeneration and neuroinflammation [85, 86] , which could support development of future therapeutic interventions in MS, but also signal possible risks of cannabinoid receptor antagonists.
In summary, several drugs have been associated with MS risk, although the complex pathophysiology of MS, together with the relatively low quality of studies, the low strength of the evidence (case reports) and discordant results for some classes of drugs call for accurate study design and reporting in future investigations.
Conclusions and Perspectives
Our systematic search identified only a limited number of studies investigating the possible role of drugs in the onset or worsening of MS: most of them are case reports and case series, which documented a possible relationship between drug and disease. This kind of contribution represents lowstrength evidence, because of the inherent reporting bias, and only an early signal of risk, which requires additional and more reliable studies. Some efforts to perform cohort and case-control studies for a few classes of drugs are documented in the literature and their results have an important role in suggesting possible associations and stimulating future studies, also by evaluating the biological plausibility.
Immunomodulators, contraceptives and antibacterials were the most frequently examined classes, for which observational studies are also available. These three classes represent different scenarios of possible interactions between drugs and MS. Evidence of direct causal relationship was shown for some immunomodulators, whereas exposure to contraceptives appears to be protective and the use of antibacterials showed conflicting results.
In all cases, the main residual confounders can be identified, especially represented by the underlying diseases that can trigger MS (antibacterials) or those that can document a susceptibility to autoimmune disease (immunomodulating agents). For hormonal contraceptives, a masking effect of MS symptoms can be supposed.
For drugs commonly used in the general population and included in some case reports (e.g. etanercept, adalimumab, fluoxetine), we suggest that surveillance be intensified by planning appropriate observational studies and by maintaining the attention on future case reports.
